Iron supplementation in renal anemia.
Iron-deficiency frequently develops in patients with chronic kidney disease who are treated with recombinant human erythropoietin (rHuEPO). It results in reduced effectiveness of anemia therapy; patients may fail to reach hemoglobin targets or may require excessively large doses of rHuEPO. It has been recognized widely that iron management, monitoring for iron deficiency, and effective iron supplementation forms a core component of anemia therapy. This review discusses the physiology of iron balance, derangements in iron balance in chronic kidney disease (CKD), and the diagnosis and treatment of iron deficiency in patients treated with rHuEPO.
Fishbane
Steven
S
Winthrop-University Hospital, Mineola, NY, USA. sfishbane@metrorenal.com
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology*; D004921:Erythropoietin / Q000008:administration & dosage; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects; D000090463:Iron Deficiencies; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D010530:Peritoneal Dialysis; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012449:Safety
D011994:Recombinant Proteins; D004921:Erythropoietin; D007501:Iron